This project seeks to develop novel immunologic therapies for allergic diseases as well as the Laboratory techniques required to understand their mechanism of action and rational application. We have developed a highly sensitive allergen specific T cell cytokine assay which allows us a direct high through put means to examine cytokine responses in clinical trials of allergen immunotherapy. This technique directly measures both the frequency and cytokine profile of antigen specific T cells and provides insight into the mechanism of action of immunomodulatory therapies. Strategies that are being pursued include the administration of rhIL-12 as an adjuvant in allergen immunotherapy as well as studies of the mechanisms of action of traditional immunotherapy. We are applying a similar approach to mouse vaccine models to understand how DNA vaccines generate specific immune responses. To date, we have developed an antigen specific assay utilizing cytometry, allowing the direct detection of complex cytokine phenotypes at the single cell level. We have examined the cytokine response to aeroallergens such as house dust, mite and cat, demonstrating a uniform Th2 response in allergic asthmatics but little or not detectable response in healthy controls. These results suggest that the normal T cell response to ubiquitous aeroallergens is tolerance. A phase I trial using rhIL-12 as an adjuvant in allergen immunotherapy has been approved by the NIAID, IRB and is waiting FDA approval. Antigen specific cytokine flow has been applied to DNA vaccination of mice, demonstrating that DNA vaccination creates a long lasting Th1 polarized immune response in both CD4+ and CD8+ subsets, whereas protein immunization generates a more transient response limited to CD4 T cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI000761-01
Application #
6099081
Study Section
Special Emphasis Panel (LAD)
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Bonville, Cynthia A; Percopo, Caroline M; Dyer, Kimberly D et al. (2009) Interferon-gamma coordinates CCL3-mediated neutrophil recruitment in vivo. BMC Immunol 10:14
Foroughi, Shabnam; Foster, Barbara; Kim, Nayoung et al. (2007) Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol 120:594-601
Cheng, Y X; Foster, B; Holland, S M et al. (2006) CD2 identifies a monocyte subpopulation with immunoglobulin E-dependent, high-level expression of Fc epsilon RI. Clin Exp Allergy 36:1436-45
Komarow, Hirsh D; Postolache, Teodor T (2005) Seasonal allergy and seasonal decrements in athletic performance. Clin Sports Med 24:e35-50, xiii
Foroughi, Shabnam; Prussin, Calman (2005) Clinical management of eosinophilic gastrointestinal disorders. Curr Allergy Asthma Rep 5:259-61
Kim, Yae-Jean; Prussin, Calman; Martin, Brian et al. (2004) Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J Allergy Clin Immunol 114:1449-55
Basta, Milan; Van Goor, Fredric; Luccioli, Stefano et al. (2003) F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 9:431-8
Prussin, Calman; Griffith, Daniel T; Boesel, Kevin M et al. (2003) Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 112:1147-54
Taylor, Steve L; Hefle, Susan L; Bindslev-Jensen, Carsten et al. (2002) Factors affecting the determination of threshold doses for allergenic foods: how much is too much? J Allergy Clin Immunol 109:24-30
McInnes, I B; Illei, G G; Danning, C L et al. (2001) IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol 167:4075-82

Showing the most recent 10 out of 13 publications